---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093294"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:10:48.171451+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Q2 net loss $30.3M; cash $267.1M; IND cleared for MRT-6160

## Summary
- Net loss $30.3M for Q2 2024 vs $32.0M in Q1; collaboration revenue $4.7M from Roche deal.
- Cash, equivalents, securities $267.1M at June 30, 2024; expected to fund operations into H1 2027.
- IND accepted by FDA for VAV1-directed MGD MRT-6160; Phase 1 SAD/MAD to start summer with data expected Q1 2025.
- MRT-2359 Phase 1/2 dose escalation ongoing at 0.75 mg 21/7 schedule; RP2D determination and updated results expected H2 2024.
- Achieved first research milestones and payments from Roche collaboration; $100M public offering completed in May.

## SEC filing metadata
- accession: 0000950170-24-093294
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017024093294/0000950170-24-093294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017024093294/glue-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093294
- JSON: https://secwatch.observer/filing/0000950170-24-093294.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093294.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.